Durban World AIDS Conference
Day 1
13th World AIDS Conference
Durban, South Africa
Tuesday, July 11, 2000
Reported by Michael Norton
Report 10
Amidst the political volleys and somewhat odd celebrations that have
characterized the first 24 hours of the 13th International AIDS Conference, were
a few items that have clinical relevance, especially in the developed world.
Here are some of those:
UNDETECTABLE VIRAL LOAD IN MONKEYS AFTER STOPPING PMPA THERAPY
Kumar, A and colleagues made an oral presentation of 4 macaque monkeys.
All four were inoculated with SHIVKU (a virus similar to HIV that causes AIDS in
macaques). 2 of the macaques were controls and did not receive antiviral
therapy. They subsequently lost cd4+'s, and after 6 months died of AIDS.
2 of the macaques received PMPA (Tenofovir = a nucleotide reverse transcriptase
inhibitor in development by Gilead and currently available to a limited number
of patients under an expanded access program). These 2 macaques
started PMPA therapy 1 week after inoculation with SHIVKU and continued taking
PMPA for 83 days. During the 1-week prior to initiation of PMPA these 2
macaques experienced a decline in cd4's that recovered to baseline during the
therapy period. During therapy the SHIV viral load became undetectable and
remained there throughout the duration of therapy. After the 83 days, PMPA was
withdrawn and the virus rebounded for several weeks prior to being brought under
control by virus specific immunity that these macaques had developed. In
contrast to their counterparts who developed AIDS quickly and died from SHIV,
these 2 macaques after 83 days of therapy have been able to mount a SHIV
specific immunity and control SHIV viremia with that immunity for greater than 1
year. Commentary by this author: These sorts of studies are
invaluable in building a body of knowledge that shows that immunity to a virus
similar to HIV can be manipulated or allowed to develop after a period of
antiviral therapy. Investigations are currently underway in humans to see
if this can be duplicated. Further information on this subject (STI's)
will be forthcoming later this week here in Durban. Most human studies appear to
need multiple interruptions to prime the immune system.
INTERMITTENT VIRAL LOAD BLIPS BETWEEN 50 to 400 COPIES/ML
Doug Ward and colleagues had a poster titled "The significance of low-level
Viremia in patients with previously undetectable HIV-1 RNA levels."
They presented 32 patients who had had 2 previous viral loads of <50
copies/ml, who then presented with a viral load between 50 and 400 copies/ml.
Upon discovery of these viral load blips, patients were asked to repeat the
viral load on follow-up visit. On subsequent viral loads, without change
of therapy, 75% returned to <50 copies/ml, all but 2 patients of those on the
very next viral load. 25% of the 32 patients who blipped did not return to
undetectable or <50 copies/ml. The authors concluded that adherence can
play an important role in why patients blip. That if a patient were
on his/her first regimen, they are more likely to return to <50 copies/ml
with simply adherence advice and the continuance of the same antiretrovirals.
This is important given the limited options available once a patient switches
regimens. On the other hand, those that were already on their 2nd or 3rd
regimen and blipped, were most likely not to return to <50 copies/ml.
Once again showing that that initial regimen is the regimen most likely to
deliver durability of viral suppression.
CONTINUE DOING PAP SMEARS EVEN IF ON HAART
Duerr, A and colleagues compared PAP results among 3 groups of women who had
<500 cd4's. Group 1 were on HAART. Group 2 were on
antiretrovirals not considered a HAART regimen (n=176). And group 3 were
receiving no HIV antiviral therapy (n=267). Twelve months after the index visit,
CD4 count had increased significantly for the HAART group (median increase
72 cells/ml) but not for the ART or no ART groups. In the HAART group
(n=159) at baseline, 26% of the women had SIL (squamous intra-epithelial
lesions) and 26% had ASCUS (atypical squamous cells of undetermined
significance). 1 year later, among the HAART group, it was found that 33%
of the women now had SIL and 17% still had ASCUS. 2 years later, once
again among the HAART group, 33% of the women still had SIL and 19% had ASCUS.
Somewhat surprising perhaps, there was no significant regression of PAP
abnormalities between the group on HAART, the group on less then HAART and the
group without any therapy. However there was a less likelihood of newly
acquired PAP abnormalities in the HAART group when compared with the other two
groups. Commentary: These results argue strongly in favor of the continued
mandate to follow HIV+ females with PAP smears every 6 months.
CAN SERUM SELENIUM LEVELS PREDICT LIPID ELEVATIONS?
In what was a new angle to this observer, Rodriguez, A and colleagues reported
on 92 of their patients who attend their research clinic in the US. They
are all HIV+ with a history of IVDU. They set out to compare their
patients who were on HAART with those who weren't and how many in each group
developed hypertriglyceridemia, hypercholesterolemia and hyperglycemia.
The most striking finding was, the significant predictive value of oncoming
hyperglycemia among the HAART group by serum levels of selenium.
DOES VIRAL LOAD HAVE TO BE BELOW 50 COPIES/ML?
Jeff Greene and colleagues in New York reached once again into their large
observational database to share an interesting item that runs contrary to
prevailing wisdom. They presented 95 patients who were divided into 2
groups starting in 1998 when the more sensitive HIV RNA assays (ultrasensitive
assay <50 copies/ml) were implemented in their clinic. In group I, 54
patients were below the level of quantification for by both the 1st generation
and 2nd generation assay, meaning their viral loads were <50 copies/ml.
In group II, 41 patients were detectable by the 2nd generation assay but not by
the 1st generation, meaning their viral loads were between 50 and 400 copies/ml.
The groups were similar when looking at age, race, risk factor, time from HIV
diagnosis, sex, time on HAART, and the total # of HAART regimens they had been
on. The results show that there was no difference among the two groups
over the examined period of approximately 2 years when comparing mean change in
cd4's, incidence of OI's, and death rates (there was no HIV related deaths in
either arm). Most strikingly, there was no difference in virologic
failure, defined as 2 consecutive viral loads > 400 copies/ml, between the
two groups. The authors concluded that optimal clinical response may not
require viral suppression to < 50 copies/ml. Commentary: These
observations, while real, are in conflict with the body of work that exists
showing that <50 copies/ml lends to a more durable virologic response when
compared to those who nadir is between 50 and 400 copies/ml. Perhaps with
more time those not < 50 copies/ml will virologically fail at higher rate,
but it is equally conceivable that if sustainable between 50 and 400 copies/ml
of HIV RNA will translate into equally efficacious clinical outcomes.
DRUG RESISTANCE TESTING: benefits & shortcomings
During the afternoon of this first day, there was a symposium of considerable
interest, chaired by Joep Lange and Joe Eron, and entitled "Management of
Drug Resistance". The speakers were Doug Mayers, John
Mellors, and B. Clotet.
>From Mayers, a slide classifying agents as being able to rapidly develop
resistance, moderately develop resistance, and slowly develop resistance.
Below are the agents and where he placed each.
Rapid/Low Resistance Barriers: 3TC - NVP - DLV - EFV
Moderate/High Barriers to Resistance: AZT - ABC - FTV/SQV - AMP - NFV - IDV -
RTV
Slow/Difficult Resistance both to develop and characterize: DDI - D4T - DDC
During the Q & A session Mayers stated that the Narval 088 study was a study
of "functional monotherapy" which we know doesn't work and is why it
showed no significant difference between the resistance and non-resistance assay
arms. He also stated that 80 plus % of patients were given DDI or D4T in
their next regimens and that the understanding of their resistance is difficult.
And that with the currently available phenotypic assays, 2 fold resistance in
D4T may mean full resistance in the presence of mutations caused by other
nucleosides, and/or a long history of prior nucleoside usage.
At Sitges, Calvez from Spain reported that he found a 1.8 fold change in
phenotypic resistance spells d4T resistance. See Resistance Workshop Reports on
NATAP web site for more details on this study.
John Mellors discussed his recent work in the area of understanding the reversal
of resistance to nucleoside RT inhibitors. He presented his groups recent
work showing that, AZT monophosphate excision is enhanced by an AZT mutant RT
enzyme, when compared to wild type. And that foscarnet by causing a
mutation at site 88, when added to a background of AZT mutatations, reduces the
excision of AZT monophosphate by that AZT and Foscarnet mutated RT enzyme.
Commentary: While this is an important development in the understanding of
the reversal of some nucleoside resistance, it may be sometime off before this
understanding can be translated into clinical success. In the opinion of
this clinician who worked with Foscarnet prior to the advent of HAART in the
fight against CMV, its toxicities are a significant hurdle.
Mellors went on to state that resistance testing does not measure adherence or
drug levels! All it allows clinicians to do is chose active drugs if they
are available.
Mellors also drove home the emerging theme with regards to phenotypic assays,
that fold cut offs for determining resistance will vary for different agents,
and may also vary with respect to patient drug history. Examples cited
were 2 .5 fold cut off for Abacavir is to low. One can get a clinically
significant response to ABC at a higher cut off. 4.0 fold increase in
susceptibility for ABT/378r is definitely not going to be appropriate and may
not hold for other PI's enhanced by Ritonavir. And also, that a 4.0 fold
cut off for NNRTI's may be too low in naÔve patients, based on recent findings
that patients starting EFV with low level baseline resistance still had a full
response to EFV if they were naÔve to the NNRTI's.
Mellors also reminded the audience that minor species are not detected by
currently available resistance assays. And that major species become minor
species within weeks when therapy is removed. He also cautioned that the
reproducibility of the genotypic assays must be improved and standardized
between labs.
During the Q & A portion, Mellors responded to an insightful question from
the audience. "Why do all the studies that look at genotyping and/or
phenotyping seem to have short end points (the longest Viradapt runs 24 weeks)?
And also, why do these studies show only small viral load differences that are
barely, if at all, statistically significant?" Mellors response
was, even a .4 log decrease in viral load translates into a clincially
significant difference and therefore it would be ethically challenging to
continue these studies for the purpose of the control arm. In responding
to the viral load differences, all of the currently completed studies look at
resistance at one point in time. The optimal usage of these tests may be
progressive/serial analysis of the major species of a patients viral population.
Thus allowing the clinician to continually choose active agents as the viral
population shifts in response to drug pressure. In one of the studies that
did show statistical significance, VIRA 3001, the patients were individuals who
were failing their first regimens. When considering M Fischl's study of
DOT among prisoners showing 100% success in first regimens after one year, one
could assume that a number of patients enrolling in this study may in fact be
patients who are not adhering well to medication. If that is the case,
this study may underestimate the power of the phenotypic assay to predict
success because these patients may in fact be patients who do not take their
drugs religiously.
B. Clotet in his presentation chimed the same chorus. He stated that GART,
VIRADAPT, VIRA 3001, and HAVANNA all give us data that point to a justification
for resistance testing, when a patient is failing one regimen that he/she is
taking as prescribed, while seeking to have the best chance at virologic
suppression with a subsequent regimen.